

YAP/TAZ-CDC42 Signaling Regulates Vascular Tip Cell Migration

Masahide Sakabe¹, Jieqing Fan², Yoshinobu Odaka², Ning Liu³, Aishlin Hassan¹, Xin Duan¹, Paige Stump¹, Luke Byerly¹, Megan Donaldson¹, Jiukuan Hao⁴, Marcus Fruttiger⁵, Qing Richard Lu¹, Yi Zheng¹, Richard Lang², Mei Xin^{1,*}

¹ Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH 45229 ² Visual Systems Group, Abrahamson Pediatric Eye Institute, Division of Pediatric Ophthalmology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, Department of Ophthalmology, College of Medicine, University of Cincinnati, Cincinnati, OH 45229 ³ Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390 ⁴ Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267 ⁵ UCL Institute of Ophthalmology, University College London, London, United Kingdom.

Submitted to Proceedings of the National Academy of Sciences of the United States of America

Angiogenesis and vascular remodeling are essential for the establishment of vascular networks during organogenesis. Here we show that the Hippo signaling pathway effectors YAP and TAZ are required, in a gene dosage-dependent manner, for the proliferation and migration of vascular endothelial cells (VECs) during retinal angiogenesis. Intriguingly, nuclear translocation of YAP and TAZ induced by *Lats1/2*-deletion blocked endothelial migration and phenocopied *Yap/TAZ*-deficient mutants. Furthermore, overexpression of a cytoplasmic form of YAP (YAPS127D) partially rescued the migration defects caused by loss of YAP and TAZ function. Finally, we found that cytoplasmic YAP positively regulated the activity of the small GTPase CDC42, deletion of which caused severe defects in endothelial migration. These findings uncover a previously unrecognized role of cytoplasmic YAP/TAZ in promoting cell migration by activating CDC42 and provide new insight into how Hippo signaling in endothelial cells regulates angiogenesis.

Hippo signaling | angiogenesis | cell migration | CDC42

Introduction

Angiogenesis is a process of growth and remodeling in vascular networks that is essential for normal development. In adulthood, angiogenesis is activated as a reparative process, for example, during wound healing (1, 2). Aberrantly regulated angiogenesis can also be a component of disease (3) and can play a key role in tumor growth and metastasis (4), inflammatory diseases (5), diabetic retinopathy, and retinopathy of prematurity (6).

Retinal angiogenesis in mice begins at postnatal day 0 (P0). The retinal vasculature initiates its expansion from the optic nerve head and migrates outwards along a preexisting network of astrocytes (7, 8). This results in the formation of the superficial vascular plexus within the retinal ganglion cell layer during the first 8 days (9, 10). Endothelial cells then migrate along nerve fibers to establish deep and intermediate vascular layers (9, 11). Cell proliferation and migration are essential for angiogenesis and these cell responses are regulated by many different signaling pathways, including the VEGF, Notch, Wnt, FGF, BMP, and integrin signaling responses (9, 12-16). VEGFA and CDC42 are known to regulate extension of the angiogenic front and filopodia formation in angiogenic tip cells (2, 17, 18).

The Hippo signaling pathway is an evolutionarily conserved, pivotal regulator of cell proliferation and organogenesis. YAP and TAZ are key components of the Hippo signaling pathway and function as transcription cofactors that regulate downstream gene expression via association with DNA binding proteins such as TEAD1-4 (19, 20). YAP and TAZ can drive the expression of genes that regulate cell proliferation and survival (*diap1*, *bantam*, *cyclin E*, and *E2F1*), the Hippo pathway (*Kibra*, *Crb*, and *Fj*), and cell-cell interaction (*E-Cadherin*, *Serrate*, *Wingless*, and *Vein*) (20). The activity of YAP and TAZ is regulated by the LATS1 and LATS2 kinases. These kinases phosphorylate YAP and TAZ, thus

preventing their nuclear translocation and regulating transcriptional activity. Although the function of YAP and TAZ in the nucleus has been subject to extensive studies (20, 21), the role of these proteins in the cytoplasm is not fully understood.

In the present study, we used the mouse postnatal retina as a model for investigating the function of YAP and TAZ during angiogenesis. We show that YAP and TAZ are required for vascular network formation by regulating endothelial cell proliferation and migration and that the influence of YAP and TAZ on angiogenesis is gene dosage-dependent. Importantly, we show that cytoplasmic YAP, but not the nuclear form, is crucial for modulating endothelial cell migration by regulating the Rho family GTPase CDC42 activity. These findings identify a previously unrecognized role of cytoplasmic YAP in regulating angiogenesis via CDC42.

Results

YAP and TAZ are required for vascular development in the retina

We examined the expression of YAP in retinal endothelial cells. YAP was detected mainly in the cytoplasm in most retinal VECs (Fig. S1A-D) and in both the nucleus and cytoplasm in some VECs (Fig. S1C and D). Whole mount retina staining also showed that YAP was mainly localized in the cytoplasm in both

Significance

New blood vessel formation is a physiological process seen in development, as well as in wound healing and tumorigenesis. Although the process of blood vasculature formation has been well documented, little is known about the molecular mechanisms that regulate endothelial migration during vascular network formation. In this study, we identified a critical role for Hippo effectors YAP and TAZ in the regulation of vascular network remodeling through controlling endothelial cell proliferation, filopodia formation, and cell migration. We found a striking cytoplasmic function of YAP in the regulation of endothelial cell migration through controlling the Rho family GTPase CDC42 activity. These findings identify a previously unrecognized YAP/TAZ function involved in the vascular network remodeling during angiogenesis.

Reserved for Publication Footnotes

137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204




Fig. 1. YAP/TAZ regulate vascular endothelial migration in the developing retina. (A-F) IB4 labeling of P5 retina vasculature from littermate *Yap^{fllox/fllox}; Taz^{fllox/fllox}* mice with *Pdgfb-iCreERT2* (*Yap/Taz* cKO) (D) or without Cre (Control) (A). Higher-magnification images of the vascular plexus and front are shown in (B, C, E, and F). (G-J) Quantification of the vascular extension (n=6), vascular area (n=3), number of branchpoints (n=6), and tip cells (n=4); mean \pm SD, * P <0.01. (K-M) Whole-mount EdU staining of P5 Control and *Yap/Taz* cKO retina. Statistical analysis of the number of EdU-positive cells is shown in (M) (n=4); mean \pm SD, * P <0.01. (N and O) Imaris image analysis of P5 retina tip cells. Arrowheads and asterisk in (N) indicate filopodia and a macrophage respectively. (P and Q) Immunohistochemistry of retinal sections of P11 eyes. Control retina shows some migrating endothelial cells (arrowheads) and the deep vascular plexus (arrows). Scale bars represent 500 μ m (A), 200 μ m (B), 100 μ m (C), and 50 μ m (K and P).

205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272




Fig. 2. Deletion of *Lats1/2* disrupts retinal vascular extension and filopodia formation. (A-F) IB4 labeling of P5 retina vasculature from Control and *Lats1^{fllox/fllox}; Lats2^{fllox/fllox}; Pdgfb-iCreERT2* (*Lats1/2* cKO) neonates. Higher-magnification images of the vascular plexus and front are shown in (B, C, E, and F). (G-J) Quantification of vascular extension (n=6), vascular area (n=4), number of branchpoints (n=4), and tip cells (n=4); mean \pm SD, * P <0.01. (K-M) Whole-mount EdU staining of P5 Control and *Lats1/2* cKO retina. Statistical analysis of the number of EdU-positive cells is shown in (M) (n=4); mean \pm SD, * P <0.01. Scale bars represent 500 μ m (A), 200 μ m (B), 100 μ m (C), and 50 μ m (K).

the migrating tip cells and the central region of retinal vessels (Fig. S1E). To determine the function of YAP in retinal VECs, we bred the conditional *Yap^{fllox/fllox}* allele with the *Pdgfb-iCreERT2* mouse line to delete *Yap* in endothelial cells in a temporally regulated manner. The expression of *Pdgfb-iCreERT2* in the developing retinal VECs was confirmed by breeding with *Rosa26-Loxp-STOP-Loxp-tdTomato* reporter mice (Fig. S2) (22). Upon tamoxifen treatment from P1 to P3, *Yap^{fllox/fllox}; Pdgfb-iCreERT2* (referred to as *Yap* cKO) mice did not show overt abnormalities when examined at P5 (Fig. S3). To investigate whether the lack of phenotype in *Yap* cKO is due to a redundant function with




Fig. 3. Phenocopy of *Cdc42* cKO filopodial loss in *Yap/Taz* and *Lats1/2* cKO. (A-F) Whole mount IB4 staining of P5 retina from Control (A) and *Cdc42^{fllox/fllox}; Pdgfb-iCreERT2* (*Cdc42* cKO) neonates (D). Higher-magnification images of the vascular plexus and front are shown in (B, C, E, and F). (G-J) Quantification of vascular extension (n=4), vascular area (n=3), number of branchpoints (n=6), and tip cells (n=3); mean \pm SD, * P <0.05, ** P <0.01, N.S.; not significant. (K-N) Comparison of filopodia formation of each genotype. Tip cells are labeled by IB4. Red arrowheads indicate filopodia. (O) Quantification of the number of filopodia per tip cell (n=4); mean \pm SD, * P <0.01. Scale bars represent 500 μ m (A), 100 μ m (B), 50 μ m (C), and 10 μ m (K).

TAZ (homolog of YAP in mammals), we generated endothelial-specific *Taz* knockout mice, *Taz^{fllox/fllox}; Pdgfb-iCreERT2* (referred to as *Taz* cKO). Similar to the *Yap* cKO mice, the *Taz* cKO mice appeared normal without an obvious vascular phenotype (Fig. S3). However, the deletion of both *Yap* alleles and one allele of *Taz*, *Yap^{fllox/fllox}; Taz^{wt/fllox}; Pdgfb-iCreERT2*, (referred to as *Yap* cKO; *Taz* cHet) led to reduced vascular density (Fig. S3) and decreased extension of the retinal vascular field (vascular extension) (Fig. S3). Furthermore, deletion of both alleles of *Yap* and *Taz* in endothelial cells, *Yap^{fllox/fllox}; Taz^{fllox/fllox}; Pdgfb-iCreERT2* (referred to as *Yap/Taz* cKO), caused a severe vascular phenotype with prominently impaired retinal vessel sprouting, vascular area, and

273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340




Fig. 4. Downregulation of CDC42 activity in YAP/TAZ deficient endothelial cells. (A) Scratch assay of Scrambled-shRNA (shScr) and YAP/TAZ-shRNA (shYAP/TAZ) infected HUVECs. Images are taken at 0 and 16 hours after cell scratch. (B) Quantification of invaded area within the scratched region of YAP/TAZ knockdown HUVEC (n=3); mean \pm SD, *P<0.01. (C) Active-CDC42 pull-down assay and western blot analysis of YAP/TAZ knockdown HUVECs. (D-E) GFP-N-WASP expression (D) and endogenous CDC42 expression (E) in YAP/TAZ knockdown HUVECs. The boxed areas are enlarged on the lower panels. Arrowheads indicate GFP-N-WASP and endogenous CDC42 expression at the edge of the cell. (F) Scratch assay of YAP/TAZ knockdown HUVECs expressing CDC42F28L. Images are taken at 0 and 12 hours after the scratch. Quantification of invaded area within the scratched region (n=3); mean \pm SD, *P<0.01. (G) Phosphorylated N-WASP expression in the retinal VECs of P11 eyes. Arrows indicate the VECs. (H) Active-CDC42 pull-down assay of P5 brain VECs. Scale bars represent 50 μ m (A and F) and 10 μ m (D).

reduced number of vascular branches (Fig. 1A-I and Fig. S3). This severe vascular phenotype persisted until later developmental stages (Fig. S4), indicating that *Yap* and *Taz* are required for vessel morphogenesis in a gene dose-dependent manner. Quantitative PCR (Q-PCR) on RNA isolated from the brain VECs of *Yap/Taz* cKO mice confirmed a significantly lower level of each transcript as well as the expression of YAP target genes, *Ctgf* and *Cyr61* (Fig. S5). Severe reduction of vascular density in *Yap/Taz* cKO mutants led us to investigate the possibility that endothelial cell proliferation was affected. 5-ethynyl-2'-deoxyuridine (EdU) was delivered to P4 pups via intraperitoneal injection 16 hours before the analysis. We found that the number of proliferating endothelial cells was greatly reduced in the *Yap/Taz* cKO retinas compared with the littermate controls (Fig. 1K-M), suggesting that YAP and TAZ are required for endothelial cell proliferation during angiogenesis.

Angiogenic sprouting is promoted by active filopodial protrusions and tip cell migration (23). To determine whether the vascular defect in *Yap/Taz* cKO mice involves tip cell migration, we examined the abundance and morphology of tip cells. The number of tip cells was significantly reduced in *Yap/Taz* cKO mice (Fig. 1C, F, J and S3E). Furthermore, tip cells in the double mutant mice exhibited only a few filopodia extending from vessel termini (Fig. 1N and O). The reduced vascular extension and the morphology of the tip cells in *Yap/Taz* cKO mice led us to investigate whether YAP and TAZ are necessary for VEC migration. During retinal angiogenesis, vasculature expands from the optic stalk at P1 and reaches the periphery by about P8 (24). VECs then migrate downwards into the regions where neurons reside to form the deep and intermediate vascular plexus by 3 weeks of age. P11 retina sections showed that there were some migrating endothelial cells and an intermediate vascular plexus in the control, but not in the *Yap/Taz* cKO retinas (Fig. 1P and Q). Whole mount CD31 staining at P13 also indicated that endothe-

lial specific deletion of *Yap* and *Taz* prevented the migration that forms the deep and intermediate vascular layers (Supplemental Movies). These data suggest that YAP and TAZ are required for endothelial cell proliferation and migration during vascular development.

Deletion of the upstream *Lats1/2* results in cell migration defect

To investigate whether other components of the Hippo signaling pathway are involved in regulating cell proliferation and migration, we deleted the upstream kinases *Lats1/2* by breeding *Lats1^{fllox/fllox}; Lats2^{fllox/fllox}* mice with *Pdgfb-iCreERT2* to generate *Lats1^{fllox/fllox}; Lats2^{fllox/fllox}; Pdgfb-iCreERT2* (referred to as *Lats1/2* cKO). This eliminates LATS-dependent phosphorylation of YAP and TAZ in endothelial cells and prevents their phosphorylation-dependent sequestration in the cytoplasm (25, 26). The *Lats1/2* cKO retinas exhibited a migration defect with reduced extension distance compared with the control mice (Fig. 2A, D, and G). The angiogenic network in *Lats1/2* cKO mice also displayed hyperplasia with increased vascular complexity evident by a 60% increase in branchpoints and reduced vascular area (Fig. 2B, E, H, and I). The proliferation rate of VECs was significantly increased whereas vascular area was reduced in *Lats1/2* cKO retina (Fig. 2K-M) and expression of YAP target genes was significantly increased in *Lats1/2* cKO endothelial cells (Fig. S5). These results contrasted with the proliferation phenotype and gene expression in the *Yap/Taz* cKO retina (Fig. 1K-M and S5). Although other effectors might be affected in the *Lats1/2* cKO mice, these data suggest that nuclear YAP/TAZ might be mainly required for VECs proliferation, but not for cell migration.

Loss of CDC42 caused abnormal vessel morphology and migration defect

The Rho GTPase CDC42 has been shown to be required for blood vessel formation during vasculogenesis by promoting filopodia formation in endothelial tip cells (17, 18, 27, 28). To




Fig. 5. Cytoplasmic YAP regulates CDC42 activity in HUVEC. (A) Scratch assay of *YAP/TAZ* knockdown HUVECs expressing Venus or YAPS127D. (B) Quantification of invaded area within the scratched region (n=3); mean \pm SD, * P <0.01, N.S.; not significant, Ven.; Venous, S127D; YAPS127D. (C) Scratch assay of *YAP/TAZ* knockdown HUVECs expressing YAPS112A. (D) Quantification of invaded area within the scratched region (n=3); mean \pm SD, N.S.; not significant, S112A; YAPS112A. (E) Active-CDC42 pull-down assay of YAPS127D-lentivirus-infected (S127D) and YAPS112A-adenovirus-infected (S112A) HUVECs. CDC42, YAP, and GAPDH expression levels are detected by western blot analysis. Scale bars represent 50 μ m (A and C).

confirm the activity of CDC42 in the formation of filopodia, we combined the *Cdc42*^{fllox/fllox} allele (29) with *Pdgfb-iCreERT2* mice to generate an endothelial specific deletion of *Cdc42*, *Cdc42*^{fllox/fllox}; *Pdgfb-iCreERT2* (referred to as *Cdc42* cKO). *Cdc42* cKO retinas exhibited reduced radial extension of vasculature at P5 (Fig 3A, D, and G). The vascular density was also reduced in *Cdc42* cKO mice (Fig. 3B, E, and I). The number of tip cells at the sprouting front did not show a significant difference between *Cdc42* cKO and the littermate controls (Fig. 3C, F and J).

Cdc42 cKO retina tip cells had few filopodia (Fig. 3M), and lacking of filopodia in tip cells was also observed in *Yap/Taz* cKO and *Lats1/2* cKO retinas (Fig. 3L, N). Quantitative analysis showed a significant decrease in filopodia density in these mice (Fig. 3O). The converging phenotype of endothelial specific deletion of *Yap/Taz*, *Cdc42*, or *Lats1/2* in the filopodia-mediated vascular sprouting and branching in the retina suggests that these molecules might operate in a common pathway in angiogenic tip cell development.

YAP and TAZ regulate CDC42 activity in migrating endothelial cells

The similar tip cell phenotype in *Yap/Taz* cKO and *Cdc42* cKO mice lead us to examine how YAP/TAZ regulates endothelial cell migration and whether YAP and TAZ regulate CDC42 activity

and its cellular localization in endothelial cells. We depleted YAP and TAZ *in vitro* in human umbilical vein endothelial cells (HUVECs) using lentiviruses expressing short hairpin RNAs targeting human *YAP* and *TAZ*, and assessed HUVECs migration by a wound healing scratch assay. To distinguish the effect of proliferation from cell migration, HUVECs were treated with hydroxyurea for 4 hours before the migration assay. Quantification analysis of the invaded area 16 hours after the scratch demonstrated that knocking down *YAP* and *TAZ* in HUVECs inhibited cell migration (Fig. 4A and B). The cell migration defect was exacerbated when both *YAP* and *TAZ* were knocked down, consistent with the mouse *in vivo* data showing that YAP and TAZ are required for cell migration and that this requirement is gene dosage-dependent.

We found that, while the total CDC42 level did not change, the level of active CDC42 was greatly reduced upon knockdown of *YAP* and *TAZ* (Fig. 4C). For better visualization of active CDC42 in a single cell, we transfected HUVECs with a GFP-tagged CDC42/RAC interactive binding domain of neural Wiskott Aldrich syndrome protein (GFP-N-WASP)(30), which binds to endogenous active CDC42. The active CDC42 was located at the lamellipodial edge of the control HUVECs (Fig. 4D). In *YAP/TAZ* knockdown HUVECs, only active CDC42 was diminished in the protruding edge (Fig. 4D), while CDC42 localization was not disrupted (Fig. 4E), suggesting that YAP and TAZ regulate CDC42 activation rather than its cellular localization in HUVECs. The migration defect in *YAP/TAZ* knockdown HUVECs can be rescued by a constitutively active form of CDC42 (CDC42F28L) (Fig. 4F), which is capable of spontaneously exchanging GDP for GTP(31, 32), suggesting that YAP/TAZ regulation of the HUVEC migration at least in part channels through CDC42 activity. To confirm the effect of *YAP/TAZ in vivo*, we examined the expression of phosphorylated-N-WASP, an effector of CDC42 (33), in the developing mouse retinal vasculature. Phosphorylated-N-WASP was detected in the migrating endothelial cells in control retinas at P11; however, the level of phosphorylated-N-WASP was greatly reduced in the *Yap/Taz* cKO retinal VECs (Fig. 4G). These data suggest that YAP/TAZ regulate cell migration through activating CDC42 mediated N-WASP pathway *in vivo*. Moreover, CDC42 activity was down regulated in the brain endothelial cells from *Yap/Taz* cKO mice. (Fig. 4H). Collectively, these observations indicate that the endothelial migration defect in the *Yap/Taz* cKO retinas is at least partially due to the downregulation of CDC42 activity.

Cytoplasmic YAP promotes endothelial cell migration

YAP is a mechanical sensor whose cellular localization changes in response to various environmental stimuli including cell-cell interaction and alterations of cytoskeletal dynamics (34, 35). We assessed whether YAP cellular localization affected CDC42 activity. When HUVECs were at low density, YAP was localized in the nucleus and translocated to the cytoplasm when cells reached confluency (Fig. S6A). Consequently, the level of phosphorylated YAP was greatly upregulated in the over-confluent cells (Fig. S6B). The active CDC42 level also increased dramatically in the over-confluent cells compared with the cells at low density (Fig. S6B). In the wound scratch assay on over-confluent HUVECs, YAP remained in the cytoplasm while the cells migrated (Fig. S6C), suggesting a pro-migratory role of the cytoplasmic YAP. The decrease of CDC42 activity in *LATS1/2* knockdown HUVEC and *Lats1/2* cKO brain endothelial cells (Fig. S6D and E) further supports the hypothesis that the cytoplasmic YAP regulates the migration of endothelial cells.

To further investigate whether cytoplasmic YAP promotes cell migration and activates CDC42, we transduced HUVECs with a lentivirus expressing YAPS127D. Substitution of Ser127 with Asp (S127D) generates a YAP protein that is sequestered in the cytoplasm mimicking phospho-YAP (Fig. S7). HUVECs

545 treated with lenti-YAPS127D migrated with a trend faster than
546 cells treated with the control lentivirus (Venus), although the
547 difference in migration did not reach significance (Fig. 5A
548 and B). YAPS127D did partially rescue the migration defects
549 caused by shRNA-mediated *YAP/TAZ* knockdown, suggesting
550 that phospho-YAP promotes endothelial cell migration (Fig. 5A
551 and B). We further examined the effect of nuclear YAP, using a
552 constitutively active form of nuclear YAP (YAPS112A, in which
553 Serine 112 is mutated to Alanine) in retinal angiogenesis, by
554 breeding *Pdgfb-iCreERT2* with transgenic mice under the control
555 of *CAG-LoxP-CAT-Stop-Loxp* cassette. No substantial effect
556 on retinal angiogenesis was detected in Tg-YAPS112A (Fig.
557 S8), suggesting that nuclear YAPS112A overexpression does
558 not alter neovasculature formation in the retina. Unlike the
559 *Lats1/2* cKO phenotype, VEC proliferation was not upregulated
560 by YAPS112A although YAP targets genes (*Ctgf* and *Cyr61*)
561 were upregulated in VECs (Fig. S8). Notably, YAPS112A did not
562 rescue the migration defect in *YAP/TAZ* knockdown HUVECs
563 (Fig. 5C and D). To examine whether this pro-migration function
564 of YAP is through activation of CDC42, we overexpressed
565 YAPS127D in HUVECs and found that the level of active CDC42
566 was greatly increased (Fig. 5E). The reduction of active CDC42
567 with shRNA-mediated *YAP/TAZ* knockdown was also rescued by
568 YAPS127D, but not by YAPS112A expression (Fig. 5E). These results
569 indicate an important role of cytoplasmic YAP in promoting
570 cell migration by activating CDC42 (Fig. S9). The partial rescue of
571 the cell migration and CDC42 activity with YAPS127D could be
572 due to the fact that only the phospho-YAP mimic is overexpressed
573 in the HUVECs in which both YAP and TAZ are knocked down.
574 Although YAP and TAZ play redundant roles in regulating retinal
575 angiogenesis, they may have distinct functions in interacting with
576 different proteins in the cytoplasm to regulate cell migration.

577 Discussion

578 Angiogenesis is a highly regulated process. This reflects the po-
579 tentially detrimental consequences of a deficiency or an excess of
580 blood vessels. The Hippo signaling pathway has been implicated
581 in vascular development (36-38) but the underlying mechanisms
582 have not been fully described. In this study, we found that the
583 cytoplasmically localized phospho-YAP, which is not involved in
584 transcription, plays an important role in promoting cell migration
585 via activating CDC42.

586 **Cell autonomous function of YAP/TAZ vascular development**
587 *in vivo*. A migration defect in epithelial-mesenchymal transition
588 (EMT) during cardiac cushion formation causes early embryonic
589 lethality instigated by deletion of a floxed *Yap* allele using *Tie2-
590 Cre*. This made it difficult to study YAP function in the developing
591 vasculature (37). Global knockdown of *Yap* via siRNA injection in
592 mice revealed that YAP is important for mediating the stability of
593 endothelial cell junction and vascular remodeling (36), however,
594 the cell autonomous function of YAP could not be addressed due
595 to the systemic distribution of the siRNA. We report here that
596 deletion of *Yap* using endothelial cell-expressing *Pdgfb-iCreERT2*
597 allows for assessment of postnatal retinal vascular development.
598 Combined endothelial deletion of *Yap* and *Taz* in mice revealed
599 gene dosage-dependent effects on retinal vascular sprouting, en-
600 dothelial cell proliferation, and migration.

601 We found that YAP target genes such as *Ctgf* and *Cyr61*
602 are down regulated in *Yap/Taz* cKO brain endothelial cells, while
603 they are up-regulated in *Lats1/2* cKO endothelial cells, suggesting
604 that transcriptional activity of YAP/TAZ might contribute to the
605 regulation of proliferation in endothelial cells. In contrast to
606 *Yap/Taz* cKO and *Lats1/2* cKO, YAPS112A overexpression
607 alone is insufficient for retinal VEC proliferation, and the level
608 or strength of YAP activity or additional factors such as TAZ
609 may control EC proliferation. Furthermore, nuclear YAPS112A
610 overexpression in transgenic mice does not alter angiogenesis

611 in the retina as opposed to the vascular defects in *Lats1/2* cKO
612 mice, suggesting that LATS1/2 could regulate other effectors,
613 in addition to the subcellular localization of YAP/TAZ for the
614 vascular morphogenesis.

615 The majority of studies of YAP and TAZ report their tran-
616 scriptional activity in the nucleus via association with TEAD
617 transcription factors and that phosphorylation of YAP and TAZ
618 by the upstream kinases induces their cytoplasmic retention and
619 degradation (20). Studies have revealed that phosphorylated YAP
620 and TAZ are associated with 14-3-3 to bind to proteins in the cy-
621 toplasmic and tight junctions (39, 40). In kidney cells, it has been
622 reported that cytoplasmic YAP and TAZ interact with angiomin
623 (AMOT) to facilitate the localization of YAP and TAZ to tight
624 junctions and to promote phosphorylation by the upstream ki-
625 nases in the Hippo pathway (41). In addition, cytoplasmically
626 localized phospho-YAP and -TAZ have been shown to interact
627 with DVL to inhibit Wnt/ β -catenin and SMAD signaling (42, 43).
628 Expression of YAPS112A in *YAP/TAZ* knockdown HUVECs
629 cannot rescue the migration defect while the cytoplasmic mutant
630 YAPS127D can, suggesting that cytoplasmic YAP but not nuclear
631 YAP is required for cell migration. Hence, our data reveal a
632 previously unrecognized function of cytoplasmic YAP/TAZ in the
633 regulation of endothelial cell migration.

634 **The crosstalk between Hippo signaling and CDC42.** The
635 small Rho family GTPase CDC42 is required for lumen forma-
636 tion during vasculogenesis and filopodia formation in endothe-
637 lial cells (17, 27, 44). When *Cdc42* was deleted in endothelial
638 cells using *Cdh5(PAC)-CreERT2* (17), vascular extension was not
639 significantly changed between the *Cdc42* mutant and littermate
640 controls. In our study, we observed a reduced vascular extension
641 phenotype using *Pdgfb-iCreERT2* to delete the floxed *Cdc42* al-
642 lele. The difference in the phenotype between these two studies
643 could be due to the distinct Cre line used and the timing of
644 tamoxifen administration. A previous study reported that dele-
645 tion of *Cdc42* in kidney progenitor cells resulted in reduced YAP
646 nuclear localization and target gene expression, suggesting that
647 CDC42 acts upstream of YAP in mouse kidney development (45).
648 Our study demonstrated that cytoplasmic YAP promoted CDC42
649 activation, providing a complementary mechanism of crosstalk
650 between the Hippo pathway and CDC42. How cytoplasmic YAP
651 regulates CDC42 activity in endothelial cell migration remains to
652 be defined. A recent study indicates that YAP regulates RhoA
653 activity through the controlling the expression of ARHGAP29
654 (Rho GTPase activating protein) (46). While CDC42 is not able
655 to be directly activated by YAPS127D, there is a possibility that
656 cytoplasmic YAP regulates CDC42-GEF or CDC42-GAP activity
657 in migrating endothelial cells. The result of the rescue experiment
658 using CDC42F28L, which can bind to GTP in the absence of GEF,
659 supports this hypothesis.

660 YAP and TAZ join a collection of cellular factors and signal-
661 ing molecules with the known ability to promote vascular sprout-
662 ing and angiogenesis. Although our findings clearly demonstrate
663 that YAP can activate CDC42 activity to promote endothelial cell
664 migration, multiple mechanisms likely contribute. More evidence
665 continues to demonstrate crosstalk between different signaling
666 pathways to control vascular development. The Notch, VEGF,
667 and BMP signaling pathways have been shown to play impor-
668 tant roles in regulating vascular sprouting and tip cell formation
669 during angiogenesis (9, 12-14). One report showed that BMP9
670 crosstalks with the Hippo pathway by repressing YAP target genes
671 in endothelial cells (47). It seems possible that, in turn, YAP and
672 TAZ could regulate BMP, Notch, and other pathways to control
673 vascular development. Future investigations would need to
674 identify the cellular mechanism underlying how cytoplasmic YAP
675 activates CDC42 and to test the potential synergistic activities
676 between YAP and regulators in other signaling pathways. The
677 new findings of cytoplasmic YAP activity may help to develop
678

681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748

pharmacologic and genetic strategies to further enhance the pro-angiogenic potential for treating patients suffering from ischemic diseases.

Materials and Methods

Animals

All animal experiments were performed with the approval of the institutional animal care and use committee of Cincinnati Children's Hospital Medical Center. Please see SI Materials and Methods for origins of knockout and transgenic mice.

Cell culture

HUVECs were maintained in EGM-2 medium (Lonza) and were infected with an adenovirus, retrovirus, and lentiviruses. Plasmid transfection was performed using PolyJet DNA In Vitro Transfection Reagent (Signagen Laboratories). Additional details can be found in SI Materials and Methods.

Immunostaining and EdU labeling.

Eyes were fixed with 4% paraformaldehyde (PFA) for 1 hour, and then retinas were incubated with IB4-FITC (Molecular Probes) overnight. For EdU studies, P4 neonates were administered an intraperitoneal (IP) injection

1. Cooke JP & Losordo DW (2015) Modulating the vascular response to limb ischemia: angiogenic and cell therapies. *Circ Res* 116(9):1561-1578.
2. Herbert SP & Stainier DY (2011) Molecular control of endothelial cell behaviour during blood vessel morphogenesis. *Nat Rev Mol Cell Biol* 12(9):551-564.
3. Carmeliet P & Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. *Nat Rev Drug Discov* 10(6):417-427.
4. Mazzone M, et al. (2009) Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. *Cell* 136(5):839-851.
5. Tas SW, Maracle CX, Balogh E, & Szekanecz Z (2016) Targeting of proangiogenic signalling pathways in chronic inflammation. *Nat Rev Rheumatol* 12(2):111-122.
6. Sapiha P (2012) Eyeing central neurons in vascular growth and reparative angiogenesis. *Blood* 120(11):2182-2194.
7. West H, Richardson WD, & Fruttiger M (2005) Stabilization of the retinal vascular network by reciprocal feedback between blood vessels and astrocytes. *Development* 132(8):1855-1862.
8. Fruttiger M, et al. (1996) PDGF mediates a neuron-astrocyte interaction in the developing retina. *Neuron* 17(6):1117-1131.
9. Gerhardt H, et al. (2003) VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. *J Cell Biol* 161(6):1163-1177.
10. Yao H, Wang T, Deng J, Liu D, & Li X (2014) The development of blood-retinal barrier during the interaction of astrocytes with vascular wall cells. *Neural Regen Res* 9(10):1047-1054.
11. Ye X, Wang Y, & Nathans J (2010) The Norrin/Frizzled4 signaling pathway in retinal vascular development and disease. *Trends Mol Med* 16(9):417-425.
12. Hellström M, et al. (2007) Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. *Nature* 445(7129):776-780.
13. Benedito R, et al. (2012) Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. *Nature* 484(7392):110-114.
14. Ricard N, et al. (2012) BMP9 and BMP10 are critical for postnatal retinal vascular remodeling. *Blood* 119(25):6162-6171.
15. Kano MR, et al. (2005) VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. *J Cell Sci* 118(Pt 16):3759-3768.
16. Zovein AC, et al. (2010) Beta1 integrin establishes endothelial cell polarity and arteriolar lumen formation via a Par3-dependent mechanism. *Dev Cell* 18(1):39-51.
17. Barry DM, et al. (2015) Cdc42 is required for cytoskeletal support of endothelial cell adhesion during blood vessel formation in mice. *Development* 142(17):3058-3070.
18. Fantin A, et al. (2015) NRP1 Regulates CDC42 Activation to Promote Filopodia Formation in Endothelial Tip Cells. *Cell Rep* 11(10):1577-1590.
19. Zhao B, et al. (2008) TEAD mediates YAP-dependent gene induction and growth control. *Genes Dev* 22(14):1962-1971.
20. Pan D (2010) The hippo signaling pathway in development and cancer. *Dev Cell* 19(4):491-505.
21. Zhao B, et al. (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. *Genes Dev* 21(21):2747-2761.
22. Claxton S, et al. (2008) Efficient, inducible Cre-recombinase activation in vascular endothelium. *Genesis* 46(2):74-80.
23. De Smet F, Segura I, De Bock K, Hohensinner PJ, & Carmeliet P (2009) Mechanisms of vessel branching: filopodia on endothelial tip cells lead the way. *Arterioscler Thromb Vasc Biol* 29(5):639-649.
24. Fruttiger M (2007) Development of the retinal vasculature. *Angiogenesis* 10(2):77-88.
25. Chen Q, et al. (2015) Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP. *Genes Dev* 29(12):1285-1297.
26. Lee DH, et al. (2016) LATS-YAP/TAZ controls lineage specification by regulating TGFβ signaling and Hnf4α expression during liver development. *Nat Commun* 7:11961.
27. Jin Y, et al. (2013) Deletion of Cdc42 enhances ADAM17-mediated vascular endothelial growth factor receptor 2 shedding and impairs vascular endothelial cell survival and vasculogenesis. *Mol Cell Biol* 33(21):4181-4197.

of 5-ethynyl-2-deoxyuridine (EdU, 5μg/g of mouse body weight). EdU incorporation was assessed using Click-IT EdU system (Invitrogen). Detailed information is described in SI Materials and Methods.

Active CDC42 assay

CDC42 activity was performed as previously described (48). Additional details can be found in SI Materials and Methods.

Statistics

All datasets were taken from $n \geq 3$ biological replicates. Data are presented as mean \pm SD. We calculated p values with unpaired Student's t test or Tukey-Kramer test with Excel (Microsoft Office); $P < 0.05$ was considered significant.

Acknowledgements

The authors thank E. N. Olson for providing the inducible Tg-Yap^{S112A} mouse line; R.L. Johnson for providing the *Lats1/2^{fllox/fllox}* mouse lines; S. Fukuhara, H. Miyoshi for providing the GFP-N-WASP and lentiviral vectors; M. Sudol for YAP^{S127D} plasmid; E. Boscolo, N. Gowri and other Xin lab members for discussion and technical assistance. Work in the laboratory of M.X. was supported by the National Institutes of Health (HL132211-01) and Cincinnati Children's Hospital.

28. Wakayama Y, Fukuhara S, Ando K, Matsuda M, & Mochizuki N (2015) Cdc42 mediates Bmp-induced sprouting angiogenesis through Fmnl3-driven assembly of endothelial filopodia in zebrafish. *Developmental cell* 32(1):109-122.
29. Chen L, et al. (2006) Cdc42 deficiency causes Sonic hedgehog-independent holoprosencephaly. *Proc Natl Acad Sci U S A* 103(44):16520-16525.
30. Ando K, et al. (2013) Rap1 potentiates endothelial cell junctions by spatially controlling myosin II activity and actin organization. *J Cell Biol* 202(6):901-916.
31. Guo F & Zheng Y (2004) Involvement of Rho family GTPases in p19Arf- and p53-mediated proliferation of primary mouse embryonic fibroblasts. *Mol Cell Biol* 24(3):1426-1438.
32. Wu WJ, Erickson JW, Lin R, & Cerione RA (2000) The gamma-subunit of the coatamer complex binds Cdc42 to mediate transformation. *Nature* 405(6788):800-804.
33. Torres E & Rosen MK (2006) Protein-tyrosine kinase and GTPase signals cooperate to phosphorylate and activate Wiskott-Aldrich syndrome protein (WASP)/neuronal WASP. *J Biol Chem* 281(6):3513-3520.
34. Wang KC, et al. (2016) Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis. *Proceedings of the National Academy of Sciences of the United States of America* 113(41):11525-11530.
35. Wang L, et al. (2016) Integrin-YAP/TAZ-JNK cascade mediates atheroprotective effect of unidirectional shear flow. *Nature*.
36. Choi HJ, et al. (2015) Yes-associated protein regulates endothelial cell contact-mediated expression of angiopoietin-2. *Nat Commun* 6:6943.
37. Zhang H, et al. (2014) Yap1 is required for endothelial to mesenchymal transition of the atrioventricular cushion. *J Biol Chem* 289(27):18681-18692.
38. Singh A, et al. (2016) Hippo Signaling Mediators Yap and Taz Are Required in the Epicardium for Coronary Vasculature Development. *Cell Rep* 15(7):1384-1393.
39. Varelas X & Wrana JL (2012) Coordinating developmental signaling: novel roles for the Hippo pathway. *Trends Cell Biol* 22(2):88-96.
40. Morrison DK (2009) The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. *Trends Cell Biol* 19(1):16-23.
41. Zhao B, et al. (2011) Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. *Genes Dev* 25(1):51-63.
42. Varelas X, et al. (2010) The Hippo pathway regulates Wnt/beta-catenin signaling. *Dev Cell* 18(4):579-591.
43. Varelas X, et al. (2010) The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-β-SMAD pathway. *Dev Cell* 19(6):831-844.
44. Bayless KJ & Davis GE (2002) The Cdc42 and Rac1 GTPases are required for capillary lumen formation in three-dimensional extracellular matrices. *J Cell Sci* 115(Pt 6):1123-1136.
45. Reginensi A, et al. (2013) Yap- and Cdc42-dependent nephrogenesis and morphogenesis during mouse kidney development. *PLoS Genet* 9(3):e1003380.
46. Qiao Y, et al. (2017) YAP Regulates Actin Dynamics through ARHGAP29 and Promotes Metastasis. *Cell Rep* 19(8):1495-1502.
47. Young K, et al. (2015) BMP9 Crosstalk with the Hippo Pathway Regulates Endothelial Cell Matricellular and Chemokine Responses. *PLoS One* 10(4):e0122892.
48. Wang HR, et al. (2003) Regulation of cell polarity and protrusion formation by targeting RhoA for degradation. *Science* 302(5651):1775-1779.
49. Xin M, et al. (2011) Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size. *Sci Signal* 4(196):ra70.
50. Xin M, et al. (2013) Hippo pathway effector Yap promotes cardiac regeneration. *Proc Natl Acad Sci U S A* 110(34):13839-13844.
51. Oka T, Mazack V, & Sudol M (2008) Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). *J Biol Chem* 283(41):27534-27546.
52. Kumar T P & Vasudevan A (2014) Isolation and culture of endothelial cells from the embryonic forebrain. *J Vis Exp* (83):e51021.
53. Chen Y, et al. (2009) The oligodendrocyte-specific G protein-coupled receptor GPR17 is a cell-intrinsic timer of myelination. *Nat Neurosci* 12(11):1398-1406.

749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816